Paradigm shifts in metastatic hormone sensitive prostate cancer (mHSPC): Recent treatment developments

The treatment of metastatic hormone-sensitive prostate cancer (mHSPC) is rapidly changing.

Published Thu, 3 Mar 2022
E CourseProstate CancerOncology
Organiser European School of Urology (ESU)
CME 1.0
Duration Approx 60 minutes

In this e-course we will address the following questions:

  • Is PSMA-PET scan the preferred imaging modality in mHSPC or are bone and CT scans sufficient?
  • What is the best treatment for men with mHSPC? Is it the combination treatment of androgen deprivation therapy (ADT) plus docetaxel or an androgen receptor signaling inhibitor (ARSi) or triplet therapy? Are any of these combination treatments for high-volume disease only?
  • What is the indication for adding radiotherapy?
  • Is there a difference between treatment for de novo disease or recurrent disease after treatment of the primary tumour?

Contact our organiser

European School of Urology (ESU)